Next 10 |
2024-03-26 08:43:16 ET More on Enveric Biosciences Enveric gains on out-licensing deal of new chemical entities for joint disease treatments Enveric stock jumps 13% on pipeline update Seeking Alpha’s Quant Rating on Enveric Biosciences Historical earni...
Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activit...
2024-03-21 08:43:23 ET Losers: Destination XL Group DXLG -16% after Q4 earnings release . Tourmaline Bio ( TRML ) -30% . Apyx Medical Corp APYX -17% after Q4 earnings release . Five Below FIVE -12% after Q4 earnings release . Designer Br...
2024-03-19 10:00:51 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
A look at the top 10 most actives in the United States Ontrak Inc. (OTRK) rose 214.5% to $0.5975 on volume of 79,666,583 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.0% to $3.7703 on volume of 36,416,698 shares Enveric Biosciences Inc. (ENVB) rose 35.5% to $1.49 on vol...
2024-03-19 08:44:10 ET More on Enveric Biosciences Enveric stock jumps 13% on pipeline update Seeking Alpha’s Quant Rating on Enveric Biosciences Historical earnings data for Enveric Biosciences Financial information for Enveric Biosciences R...
2024-03-19 07:58:49 ET DENVER, Colo., Mar 19, 2024 ( 247marketnews.com )- Enveric Biosciences (NASDAQ: ENVB ) stated, this morning, that it signed two non-binding term sheets to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmac...
Second biotechnology company to potentially out-license novel compounds from Enveric’s portfolio of assets with possible significant milestone payments and royalties Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology compa...
Patents extend compositional protection to proprietary compounds Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of d...
2024-03-07 11:29:12 ET More on Clearmind Medicine, Bright Minds, etc. Mind Medicine (MindMed) Inc. (MNMD) Q4 2023 Earnings Call Transcript Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...
News, Short Squeeze, Breakout and More Instantly...
Enveric Biosciences Inc Com Company Name:
ENVB Stock Symbol:
NASDAQ Market:
Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activit...
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS...
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling around 100 points on Tuesday. Following the market opening Tuesday, the Do...